Direct Oral Anticoagulants (DOACs) Market Key Highlights:
- Market Size (2024): USD 47.36 Billion
- Projected Market Size (2034): USD 102.24 Billion
- CAGR (2023-2034): 8%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Direct Oral Anticoagulants (DOACs) Market Definition
The direct oral anticoagulants (DOACs) market refers to the segment of the pharmaceutical industry focused on the development, production, and sale of DOAC drugs, that are used for various aims such as in the prevention and treatment of clot formation. There is a growing demand for DOACs especially for the treatment of various thromboembolic disorders mainly because of their effectiveness, safety, and ease of use in comparison to conventional anticoagulants such as warfarin.
The direct oral anticoagulants (DOACs) market is predicted to expand owing to their quick acceptance and use in the thrombus-loading patient groups. The supply of such anticoagulants is ensured by the advancement in the quality of modern anticoagulant therapy, being an option for warfarin. They ensure consistent effectiveness, and fixed dosage irrespective of the monitored level, hence, offer a potential market. The cases of Venus thromboembolism among the cancer population are also anticipated to rise. Within North America, it is expected that North America will share a large sector of the market owing to the fast adoption of novel anticoagulants and the increasing population of atrial fibrillation patients. An increase in the consumption of these classes of anticoagulants can also be attributed to the rising awareness of the new therapies and the increased demand resulting from a large patient population in developing countries.
Direct Oral Anticoagulants (DOACs) Market Segmentation:
By Type
- Oral Factor Xa Inhibitors
- Direct Thrombin Inhibitors (DTIs)
By Application
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Other
Direct Oral Anticoagulants (DOACs) Market Companies:
- Bristol Myers Squibb
- Pfizer
- Daiichi Sankyo
- Janssen Pharmaceuticals
- Bayer
- Viatris
- Boehringer Ingelheim
- Accord Healthcare
- Sandoz
- Teva Pharmaceutical
- Mylan
- Apotex
- GlaxoSmithKline.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
